COMMUNIQUÉS West-GlobeNewswire

Outliyr's Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power
09/07/2026
Outliyr's free public database catalogs more than seventy red light therapy panels and other light therapy devices, and publishes its own spectrometer measurements next to manufacturer claims for the units it has tested [...]
UPDATE: Endogenex Announces Full Enrollment of the ReCET Clinical Study
08/07/2026
350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes MINNEAPOLIS, July 08, 2026 (GLOBE NEWSWIRE) -- Endogenex, a [...]
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
08/07/2026
SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in [...]
BrightSpring Health Services, Inc. to Announce Second Quarter 2026 Financial Results on July 31, 2026
08/07/2026
LOUISVILLE, Ky., July 08, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its second quarter 2026 financial results [...]
Cascade Prodrug and Uneedle Advance Collaboration to Enable Suprachoroidal Delivery of CPD100 for Wet AMD
08/07/2026
PORTLAND, Ore. and ENSCHEDE, The Netherlands, July 08, 2026 (GLOBE NEWSWIRE) -- Cascade Prodrug Inc. and Uneedle are advancing their collaboration to evaluate CPD100, Cascade’s first-in-class hypoxia-targeted [...]
Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases
08/07/2026
CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an [...]
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
08/07/2026
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Range Impact Announces Vin Ferrara, MD, MBA, Has Joined the Company as Vice President, Real Estate
08/07/2026
CLEVELAND, OHIO, July 08, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing former industrial and mine [...]
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
08/07/2026
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near- [...]
Vaxcyte to Participate in Upcoming Investor Conferences
08/07/2026
SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
08/07/2026
ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' [...]
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08/07/2026
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Half-Year Report on Liquidity Contract with Invest Securities
08/07/2026
NANTES, France, July 8, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) – Under the liquidity contract entrusted by OSE Immunotherapeutics to Invest Securities, the following resources [...]
SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1)
08/07/2026
Approximately $40 million in cash and more than $15 million in short-term investment assets as of June 30, 2026 1 Estimated net asset value of approximately $60 million and no debt outstanding as of June 30, 2026¹ [...]
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
08/07/2026
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 08 juillet 2026 – GENFIT (Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies [...]
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
08/07/2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]
Sienna Announces Second Quarter 2026 Results Release Date and Conference Call
08/07/2026
MARKHAM, Ontario, July 08, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2026 second quarter results after market close on Tuesday, [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
08/07/2026
Nantes, le 8 juillet 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
Bilan semestriel du contrat de liquidité avec Invest Securities
08/07/2026
NANTES, France, le 8 juillet 2026, 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) – Au titre du contrat de liquidité confié par OSE Immunotherapeutics à Invest Securities, les moyens suivants [...]

Pages